Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.
OBJECTIVE
To develop more effective chemotherapy regimens for childhood acute myelogenous leukemia (AML).


METHODS
Between June 1991 and December 1996, we administered the nucleoside analog 2-chlorodeoxyadenosine (2-CDA) to 73 children with primary AML and 20 children with secondary AML or myelodysplastic syndrome (MDS). Patients received one or two 5-day courses of 2-CDA (8.9 mg/m(2)/d) given by continuous infusion. All patients then received one to three courses of daunomycin, cytarabine, and etoposide (DAV) remission induction therapy.


RESULTS
Seventy-two patients with primary AML were assessable for response. Their rate of complete remission (CR) was 24% after one course of 2-CDA, 40% after two courses of 2-CDA, and 78% after DAV therapy. Of the 57 patients who entered CR, 11 subsequently underwent allogeneic bone marrow transplantation (BMT), and 40 underwent autologous BMT. Twenty-nine patients remain in continuous CR after BMT. Two patients remain in CR after chemotherapy only. The 5-year event-free survival (EFS) estimate was 40% (SE = 0.080%). Patients with French-American-British (FAB) M5 AML had a higher rate of CR after treatment with 2-CDA (45% after one course and 70.6% after two courses) than did others (P =.002). In contrast, no patient with FAB M7 AML (n = 10) entered CR after treatment with 2-CDA. Similarly, no patient with primary MDS (n = 6) responded to 2-CDA. Seven patients with secondary AML or MDS (n = 14) had a partial response to one course of 2-CDA.


CONCLUSIONS
This agent was well tolerated, and its toxicity was acceptable. Future trials should examine the effectiveness of 2-CDA given in combination with other agents effective against AML.
Krance
R A
RA
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN, USA. rakrance@bcm.tmc.edu
Hurwitz
C A
CA
Head
D R
DR
Raimondi
S C
SC
Behm
F G
FG
Crews
K R
KR
Srivastava
D K
DK
Mahmoud
H
H
Roberts
W M
WM
Tong
X
X
Blakley
R L
RL
Ribeiro
R C
RC
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D017338:Cladribine / Q000008:administration & dosage / Q000494:pharmacology*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D017338:Cladribine